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BACKGROUND: Although the role of Th17 and regulatory T cells in 
the progression of atherosclerosis has been highlighted in recent years, 
their molecular mediators remain elusive. We aimed to evaluate the 
association between the CD69 receptor, a regulator of Th17/regulatory T 
cell immunity, and atherosclerosis development in animal models and in 
patients with subclinical disease.
METHODS: Low-density lipoprotein receptor–deficient chimeric mice 
expressing or not expressing CD69 on either myeloid or lymphoid cells 
were subjected to a high fat diet. In vitro functional assays with human 
T cells were performed to decipher the mechanism of the observed 
phenotypes. Expression of CD69 and NR4A nuclear receptors was 
evaluated by reverse transcription–polymerase chain reaction in 305 
male participants of the PESA study (Progression of Early Subclinical 
Atherosclerosis) with extensive (n=128) or focal (n=55) subclinical 
atherosclerosis and without disease (n=122).
RESULTS: After a high fat diet, mice lacking CD69 on lymphoid cells 
developed large atheroma plaque along with an increased Th17/regulatory 
T cell ratio in blood. Oxidized low-density lipoprotein was shown to 
bind specifically and functionally to CD69 on human T lymphocytes, 
inhibiting the development of Th17 cells through the activation of 
NR4A nuclear receptors. Participants of the PESA study with evidence of 
subclinical atherosclerosis displayed a significant CD69 and NR4A1 mRNA 
downregulation in peripheral blood leukocytes compared with participants 
without disease. The expression of CD69 remained associated with the risk 
of subclinical atherosclerosis in an adjusted multivariable logistic regression 
model (odds ratio, 0.62; 95% CI, 0.40–0.94; P=0.006) after adjustment for 
traditional risk factors, the expression of NR4A1, the level of oxidized low-
density lipoprotein, and the counts of different leucocyte subsets.
CONCLUSIONS: CD69 depletion from the lymphoid compartment promotes 
a Th17/regulatory T cell imbalance and exacerbates the development of 
atherosclerosis. CD69 binding to oxidized low-density lipoprotein on T cells 
induces the expression of anti-inflammatory transcription factors. Data from 
a cohort of the PESA study with subclinical atherosclerosis indicate that 
CD69 expression in PBLs inversely correlates with the presence of disease. 
The expression of CD69 remained an independent predictor of subclinical 
atherosclerosis after adjustment for traditional risk factors.
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Although lipid deposition in the vessel wall is the hallmark of atherosclerosis, for many years, it has been recognized that inflammation also 
plays a crucial role in the genesis and progression of the 
disease and the appearance of clinical manifestations 
(infarction, stroke).1 Recently, it has been demonstrated 
that the modulation of the inflammatory response is 
a valid target to reduce the risk of atherothrombotic 
events in high-risk patients.2 The interplay between lip-
id metabolism and immune response is not completely 
understood. In the last decade, the contribution of lym-
phocytes to atherosclerosis clinical manifestations has 
been highlighted, and effector T-cell responses seem to 
be exacerbated in hyperlipidemia.3,4
In vivo models of atherosclerosis suggest that regu-
latory T (Treg) cells suppress inflammatory responses 
and attenuate atherosclerosis.5 Experimental therapies 
aimed to increase Treg cell population under high fat 
diet (HFD) conditions have conclusively demonstrated 
an important role for this T-cell subset in atherosclerosis 
attenuation.6,7 The role of Th17 lymphocytes is more 
controversial. Although genetic or pharmacological in-
hibition of interleukin (IL)-17 significantly ameliorates 
atherosclerosis,8,9 concomitant increases in both IL-17 
and IL-10 lead to smaller plaques.10 Another study re-
ports bigger plaques in ApoE−/−IL-17−/− mice.11 A Th17/
Treg imbalance has been reported in patients with coro-
nary artery atherosclerosis, with a significant increase in 
Th17 and a decrease in Treg cells.12,13
The early lymphocyte activation antigen CD69 regu-
lates Th17 and Treg cell differentiation. CD69-deficient 
mice display enhanced Th17 differentiation and defec-
tive Treg cell function,14–16 resulting in an inability to 
resolve inflammation or to maintain immune tolerance 
in diseases such as arthritis, asthma, contact dermati-
tis, or myocarditis.17–19 However, no differences were 
observed in the atheroma plaque formation in CD69−/− 
ApoE−/− mice.20
A key event in the process of atheroma plaque for-
mation is low-density lipoprotein (LDL) peroxidation, 
which generates highly inflammatory and immunogen-
ic oxidized LDL (oxLDL).21 However, oxLDL can also elicit 
anti-inflammatory responses by activating peroxisome 
proliferator-activated receptor-γ22 and liver X receptor 
or by upregulating transcription factors with anti-in-
flammatory activity such as NR4A nuclear receptors.23,24
The main objectives of this work were to analyze the 
role of CD69 lymphocyte expression in atherosclerosis 
development, the immune mechanisms involved, and 
its relation with human disease. Using chimeric ldlr−/− 
mice subjected an HFD as atherosclerosis model, we 
show that CD69 deficiency specifically on lymphocytes 
leads to an altered Th17/Treg equilibrium and a conse-
quent increase in atheroma plaque size during an HFD. 
In vitro assays in human T cells showed that the interac-
tion between oxLDL and CD69 activates the expression 
of NR4A transcription factors, skewing T cells toward 
a regulatory phenotype and dampening Th17 and Th1 
responses. Thus, we describe an unexpected regulatory 
mechanism of the adaptive immune system that delays 
atherosclerosis development in hyperlipidemic condi-
tions. Remarkably, our data from participants in the 
PESA (Progression of Early Subclinical Atherosclerosis) 
cohort25 were in agreement with these results in that 
downregulated CD69 expression in peripheral blood 
leukocytes (PBLs) is associated with subclinical athero-
sclerosis in an adjusted multivariable logistic regression 
model.
METHODS
The data, methods, and study material will be available to 
other researchers for purposes of reproducing the results or 
replicating the procedures by contacting the corresponding 
authors.
Study Design
To analyze the role of CD69 during atherosclerosis develop-
ment, we used chimeras from ldlr−/− CD45.1+ mice (the line 
was obtained in house by crossing and subsequent selection 
by genotype of B6;129S7-Ldlrtm1Her/J with B6.SJL-PtprcaPepcb/
BoyCrl, from Jackson and Charles River, respectively) and 
CD69−/− or CD69+/+ B6 double reporter (dRep) for Treg cells 
(FIR mice, Foxp3–monomeric red fluorescent protein [mRFP]) 
Clinical Perspective
What Is New?
• This study identifies CD69 as an oxidized low-
density lipoprotein receptor in T lymphocytes that 
contributes to the regulatory action of the adap-
tive immune system, preventing atherosclerosis 
development.
• CD69 controls the onset and progression of athero-
sclerosis, and its mRNA expression is an indepen-
dent marker of early subclinical disease in humans.
• Data from a cohort of asymptomatic individuals 
indicate that CD69 expression in circulating T cells 
correlates inversely with the presence and exten-
sion of subclinical atherosclerosis.
• The expression of CD69 remained associated with 
the risk of subclinical atherosclerosis after adjust-
ment for traditional cardiovascular risk factors.
What Are the Clinical Implications?
• Oxidized low-density lipoprotein binding to CD69 
confers a regulatory phenotype to human and 
mouse T cells, dampening Th17 responses and 
ameliorating atherosclerosis.
• Expression of CD69 in circulating cells might serve 
as a new biomarker for the presence of subclinical 
atherosclerosis.
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and Th17 cells (IL-17A–IRES–enhanced green fluorescent 
protein [eGFP]), hereafter cd69−/−dRep and cd69+/+dRep, 
respectively. dRep mice allow us to monitor the presence of 
live Treg cells and Th17 cells throughout the experiment. To 
evaluate the influence of immune cell CD69 expression dur-
ing atherosclerosis development, Ldlr−/− mice were irradiated 
and reconstituted with bone marrow (BM) from cd69−/−dRep 
mice or cd69+/+dRep. Next, atherosclerosis development was 
evaluated in mice proficient or deficient for CD69 only in the 
myeloid compartment (MC; hereafter MC cd69+/+ and MC 
cd69−/−) or lymphoid compartment (LC; hereafter LC cd69+/+ 
and LC cd69−/−). For a detailed description of chimeric mice 
design, see the online-only Data Supplement. After 6 weeks 
of BM reconstitution, mice were placed on an HFD (SSNIFF, 
S9167-E010) for 10 to 16 weeks. Immune response was 
evaluated in peripheral blood, draining (para-aortic) lymph 
nodes (LNs), nondraining (inguinal, axillary, mesenteric) LNs, 
and spleen by flow cytometry and quantitative polymerase 
chain reaction (PCR). All animal procedures were approved 
by the ethics committee of the Comunidad Autónoma de 
Madrid and conducted in accordance with the institutional 
guidelines that comply with the European Institutes of 
Health directives (2010/63/EU of the European Parliament 
and the Council on the Protection of Animals Used for 
Scientific Purposes [Official Journal of the European Union, 
2010:53:33–79]).
Quantification of CD69 and NR4A Gene 
Expression in the PESA Study
Expression of CD69 and nuclear receptors NR4A1 was eval-
uated by reverse transcription PCR with Taqman probes in 
PBLs of a subset of the participants from the PESA study.25 
This study prospectively enrolled 4184 asymptomatic par-
ticipants 40 to 54 years of age to evaluate the systemic 
extent of atherosclerosis in the carotid, abdominal aortic, 
and iliofemoral territories by 2-dimensional/3-dimensional 
ultrasound and coronary artery calcification by computed 
tomography at baseline and 3 and 6 years after enrollment 
for follow-up studies. Participants were then defined as free 
of atherosclerosis (no disease; no presence of plaque and a 
coronary artery calcium score of zero) or with evidence of 
focal (1 site affected) or generalized (4–6 sites affected) sub-
clinical atherosclerotic disease.25 Following a general study 
strategy (ie, not for this specific analysis), 480 individuals 
of the whole cohort were retrospectively selected on the 
basis of the extent of subclinical atherosclerosis to perform 
molecular tests. Individuals were included in this subcohort, 
prioritizing those with more territories with evidence of 
plaque at baseline. For those presenting a tie, individuals 
with coronary artery calcification score ≥1 were included. 
Control subjects were then selected from those individuals 
without plaques and matched with the chosen cases on the 
basis of age, sex, family history of cardiovascular disease, 
dyslipidemia, and hypertension. From this subpopulation of 
480 individuals, we selected 305 male participants classified 
as without disease (n=122) or with focal (n=55) or gener-
alized (n=128) disease to test the expression of CD69 and 
NR4A1 by reverse transcription PCR. General characteristics 
of this specific subcohort are shown in Table I in the online-
only Data Supplement.
Monitoring Th17 and Treg Cells in the In 
Vivo Model
To assess the immune response, the percentages of IL-17–
eGFP+ or Foxp3-RFP+ cells in peripheral blood CD4+ T cells 
were monitored throughout the experiment by flow cytom-
etry. The presence of Th17 and Treg cells was also evaluated 
at the end point of the experiment in aortic arch, spleen, non-
draining (axillary) LNs, and draining (para-aortic) LNs.
OxLDL Binding Assays
Jurkat T (JK) cells or rat basophilic leukemia (RBL) cells sta-
bly transfected or not with CD69 were incubated with 
1,1’-dioctadecyl-3,3,3’,3’-tetramethylindo-carbocyanine per-
chlorate–labeled (Dil) LDL in their native and oxidized form 
in the presence or not of unlabeled lipoproteins. Lipoprotein 
binding was determined with flow cytometry. In some cases, 
blocking anti-CD69 antibody was added.
Human CD4+ T Cell Polarization
For human Th1, Th17, and Treg cell polarization, CD4+ T 
cells were purified from peripheral blood of healthy donors 
and incubated with a specific cocktail of recombinant cyto-
kines. After the indicated days of culture, cells were ana-
lyzed in a FACSCanto Flow Cytometer. When indicated, 
oxLDL (50 µg/mL) and anti-CD69 (20 µg/mL) were added 
to the cultures.
Assessment of CD69 and NR4A 
Transcripts
Expression of mRNA levels of CD69 and NR4A nuclear 
receptors was analyzed in PBLs from patients with subclini-
cal atherosclerosis and healthy subjects with reverse tran-
scription PCR with Taqman probes (Applied Biosystems). 
Expression of NR4A receptors was also assessed in Jurkat T 
cells and human primary lymphocytes in the presence or not 
of oxLDL. When indicated, blocking anti-CD69 antibodies 
were also added. NR4A and CD69 mRNA expression was 
also determined in para-aortic LNs and peripheral blood lym-
phocytes from mice.
Tissue Processing and 
Immunohistochemistry
For plaque area assessment, 5-µm-thick sections at 100-µm 
intervals were collected starting at the origin of the aortic 
valve cusps. Sections were stained with Oil Red O staining, 
(Sigma-Aldrich) and hematoxylin, and lesion size was ana-
lyzed with ImageJ software. For Masson trichrome stain-
ing, 7-µm-thick sections at 100-µm intervals were collected. 
Sections were stained with the Masson-Goldner staining kit 
(Merck). For specific staining, anti-F480 antibody was pur-
chased from Abcam (ab6640) and anti-CD3 from Santa Cruz 
Biotechnology (sc-1127). OxLDL was detected by immunoflu-
orescence with rabbit anti-mouse oxLDL from Abcris.
Statistical Analysis
In vivo experiments were performed according to a ran-
domized complete block design (treatments and different 
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time points have been taken into account) or a fully ran-
domized design. To determine significant differences 
between 2 means, P values were calculated by unpaired t 
test or Mann-Whitney U test according to normality test, 
and differences among >2 means were analyzed by 1-way 
ANOVA or the Kruskal-Wallis test. To account for multiple 
comparisons, the Tukey or Bonferroni posttests were used 
to compare selected pairs of means and all pairs of means, 
respectively. When indicated, the Wilcoxon signed-rank test 
was used to analyze paired data. For differences in human 
T-cell differentiation assays, data were analyzed with the 
Friedman test and the Dunn multiple-comparison test. In 
kinetic experiments with the same mice, 2-way repeated-
measures ANOVA with the Sidak multiple-comparison post 
hoc test was performed. Differences were considered sig-
nificant at P<0.05.
Table I in the online-only Data Supplement shows demo-
graphics and cardiovascular risk factor statistics of the PESA 
subcohort selected for the quantitative PCR assay. Statistics 
were calculated with Stata (StataCorp, College Station, TX). 
Data are expressed as mean±SD, median and interquartile 
range, or number (percent). P values are derived from ANOVA 
for log-transformed continuous variables and χ2 for categori-
cal variables, except for those variables with n<6, for which 
the Fisher test was used.
The Cuzick extension of the Wilcoxon rank-sum test was 
used to assess the significance of the trend in the quantita-
tive PCR data across the 3 ordinal groups allowing for ties. 
After that, 1-way ANOVA followed by the Tukey posttest 
was used to identify significant differences between each 
stage of subclinical atherosclerosis and baseline. Expression 
levels measured by quantitative PCR were normalized and 
considered in the log2 scale to fulfill the normality assump-
tion. We then focused on the 2 most extreme groups (no 
disease versus generalized disease) and used a multivariable 
logistic regression model to assess the association of CD69 
with subclinical atherosclerosis independently of known 
cardiovascular risk factors (age, smoking, family history of 
cardiovascular disease, dyslipidemia, hypertension, diabetes 
mellitus), the expression of NR4A1, oxLDL levels, and vol-
ume of different leukocyte subsets. These variables included 
in the model were found to be statistically significant with 
a value of P<0.1 in a univariable logistic regression model. 
Odds ratio, 95% CI, and P value are reported. Traditional 
cardiovascular risk factors were determined from blood sam-
ples and interviews as follows: (1) diabetes mellitus: fasting 
plasma glucose ≥126 mg/dL or treatment with insulin or oral 
hypoglycemic medication; (2) arterial hypertension: systolic 
blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 
mm Hg, or use of antihypertensive medication; (3) hypercho-
lesterolemia: total cholesterol ≥240 mg/dL, LDL cholesterol 
≥160 mg/dL, high-density lipoprotein cholesterol <40 mg/dL, 
or use of lipid-lowering drugs; (4) smoking: current smoking 
status and a lifetime consumption of >100 cigarettes; and 
(5) family history of cardiovascular disease: first-degree rela-
tive diagnosed with atherosclerosis before 55 years of age 
in men and 65 years of age in women. Linear regression 
models were used to assess the correlation between the 
expression levels of CD69 with NR4A1 receptors. All these 
analyses were implemented with the R statistical software 
(www.r-project.org).
RESULTS
Lack of CD69 on Lymphocytes 
Exacerbates Atherosclerotic Plaque 
Formation
To evaluate the role of CD69 expression on BM-derived 
cells in the development of atherosclerosis, male Ldlr−/− 
mice were irradiated and reconstituted with BM from 
cd69−/− dRep for Foxp3-mRFP and IL-17A–eGFP26 mice 
(BM Cd69−/−) or WT-dRep littermates (BM Cd69+/+; Fig-
ure IA in the online-only Data Supplement). From week 
13 on, we found increased Th17/Treg cells ratio in PBLs 
of chimeric mice (Figure IB in the online-only Data Sup-
plement), indicating a polarization toward proinflam-
matory phenotype in the absence of CD69. After 10 
weeks of HFD, mice reconstituted with cd69−/−dRep BM 
displayed a significantly high increase in IL-17–eGFP+ 
cells in para-aortic LNs, with higher absolute numbers 
compared with BM Cd69+/+ mice (Figure IC and ID in 
the online-only Data Supplement). In agreement, the 
percentage but not cell numbers of Foxp3mRFP+ cells 
was significantly reduced in the absence of CD69 (Fig-
ure ID in the online-only Data Supplement), indicating 
that Treg cell recruitment to para-aortic LNs is not com-
promised. The percentage of CD4+ IL-17–eGFP+ cells 
was increased in the aortic arc of BM Cd69−/−chimeras, 
whereas there is a tendency for decreased CD4+ and 
FoxP3+ cells (Figure IE and IF in the online-only Data 
Supplement). Collectively, flow cytometry data indi-
cate that hyperlipidemia induces high proinflamma-
tory activity and a disrupted Th17/Treg cells balance in 
the absence of CD69. Histochemical studies revealed 
more extensive lesions and necrotic cores in aortic 
valves from BM Cd69−/− chimeras compared with the 
BM Cd69+/+ control group (Figure IG and IH in the on-
line-only Data Supplement). Atheroma plaques in both 
groups consisted mainly of F4/80+ foam cells, although 
we found a higher infiltration of CD3+ lymphocytes 
into atheroma plaques in the BM Cd69−/− group (Figure 
II and IJ in the online-only Data Supplement). Peripher-
al blood leukocytes were analyzed during an HFD with 
no significant changes between BM Cd69+/+ and BM 
Cd69−/− mice (Figure IIA and IIB in the online-only Data 
Supplement). Because CD69 has been also related to 
the maintenance of T-cell helper memory,27 the CD44hi 
CD62Llo memory T-cell subset was also analyzed. Naïve 
T cells decrease with an HFD whereas memory T cells 
increase in both chimeric mice, suggesting that CD69 
is not playing a role in the maintenance of T-helper 
memory cells in this model (Figure IIC in the online-
only Data Supplement). Moreover, we found that the 
ratio between dendritic cells and Treg cells during HFD 
remains equal in both chimeric mice (Figure IID in the 
online-only Data Supplement). These data suggest that 
Th17 and Treg cell proportions are altered under the 
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course of HFD in BM Cd69−/− chimeric mice, whereas 
the other leukocyte subsets remained unaltered.
To address whether the observed phenotype in BM 
Cd69−/− mice is specific to the LC or MC, we generated 
mixed BM chimeras proficient or deficient for CD69 in 
either the LC (LC Cd69+/+ and LC Cd69−/− groups) or MC 
(Figure 1A and Figure III in the online-only Data Supple-
ment). The specific deletion of CD69 on lymphocytes 
and myeloid cells was confirmed by flow cytometry 
analysis in the blood of hyperlipidemic mice (Figure 1A). 
We observed a significantly enhanced plateau of Th17 
response in the peripheral blood of the LC Cd69−/− group 
after HFD, whereas percentages of Foxp3 cells were sig-
nificantly decreased compared with the Cd69+/+ group 
(Figure  1B and 1C). On observation that peripheral 
Th17 responses started to diminish in the LC Cd69−/− 
group after week 16 on HFD (Figure 1C), mice were eu-
thanized, and immune responses and plaque formation 
were assessed. IL-17–eGFP+ cells in para-aortic LNs from 
LC Cd69−/− mice were once again increased, whereas 
the percentages of Foxp3mRFP+ cells were comparable 
in the 2 groups (Figure  1D). However, the absolute 
number of Treg cells was significant decreased, with a 
significant increase in the number of Th17 cells (Fig-
ure 1D). Finally, atherosclerotic lesions were significantly 
more advanced with more extensive necrotic cores in 
the LC Cd69−/− group as assessed by Oil Red O and Mas-
son trichrome staining (Figure 1E and 1F).
Myeloid cells are pivotal for atherosclerosis develop-
ment.28,29 We next performed mixed BM chimeras pro-
ficient or deficient for CD69 in the MC (MC Cd69+/+ 
and MC Cd69−/−; Figure IIIA in the online-only Data 
Supplement). We did not detect differences during 
HFD in Th17 or Treg cell dynamics in the periphery, at 
the site of inflammation (para-aortic LNs; Figure IIIB 
through IIID in the online-only Data Supplement), or in 
atheroma plaque formation (Figure IIIE and IIIF in the 
online-only Data Supplement). All the CD69-proficient 
and -deficient groups gained similar amounts of weight 
throughout the experiment. However, the circulating 
levels of lipids (free fatty acids, triglycerides, high-den-
sity lipoprotein, LDL, and cholesterol) were lower in LC 
Cd69−/− compared with LC Cd69+/+, suggesting that the 
enhanced plaque formation in LC Cd69−/− was not at-
tributable to a metabolic defect (Figure IVA through IVC 
in the online-only Data Supplement).
We conclude that specific CD69 deletion in the LC 
accounts for the increased proinflammatory phenotype 
and the enhanced atheroma plaque formation.
OxLDL Binds to CD69 on T Lymphocytes
The main receptor of oxLDL on vascular cells is lectin-like 
oxLDL receptor-1 (LOX-1), located in the same chromo-
somal locus immediately upstream to CD69. The LOX-1 
and CD69 C-type lectin-like domains form very similar 
dimers (Figure 2A, left), unlike other C-type lectins such 
as dectin-1 or the macrophage mannose receptor (Fig-
ure V in the online-only Data Supplement). In LOX-1, 
the oxLDL-binding surface is located at the top of the 
dimer and contains a unique basic “spine” formed by 
the diagonal arrangement of arginine residues across 
the dimer surface (Figure 2A, top right).30,31 Electrostatic 
surface representation of the CD69 C-type lectin-like 
domain dimer indicated that 4 arginine residues cluster 
at the center of the dimer and form a basic spine, simi-
lar to that of LOX-1 (Figure 2A, bottom right). Because 
this structural feature is proposed to be important for 
oxLDL recognition,30 we hypothesized that CD69 bind-
ing to oxLDL particles could account for the phenotype 
observed in vivo.
Transfected Jurkat T cells stably expressing CD69 
(JKCD69) on their surface bound oxLDL-DiI much more 
efficiently than untransfected JK (JKwt) cells (Figure 2B 
and 2C). JKCD69 cells bound oxLDL in a dose-depen-
dent manner and showed a weaker binding of native 
LDL (Figure 2D). This binding was able to induce CD69 
internalization in JKCD69 cells (Figure 2E). The specific-
ity of oxLDL binding to CD69 was confirmed in blocking 
assays with anti-CD69 antibodies (Figure 2F).
CD69/oxLDL Binding Controls Th17/Treg 
Equilibrium and Expression of NR4A 
Nuclear Receptors
OxLDL exposure significantly reduced the mRNA levels 
of IL-8 and interferon-γ (IFN-γ) produced by JKCD69 
cells but not in JKwt cells after activation (Figure 3A). 
Because of the role of CD69 in effector T-cell differ-
entiation,16 we evaluated human T-cell differentiation 
to effector phenotypes. Challenge of human CD4+ T 
cells with oxLDL diminished the percentage of IL-17+ 
and IFN-γ+ cells generated in response to Th17- or Th1-
polarizing stimuli (Figure 3B and 3C) and favored Treg 
differentiation (Figure 3D). This effect was dependent 
on CD69, as demonstrated by the blockade with anti-
CD69 antibodies (Figure 3B through 3D).
The NR4A orphan nuclear receptors have emerged 
as key regulators of the immune response, controlling 
the magnitude of the inflammatory processes; NR4A1 
and NR4A3 are crucial for Treg cell development.23,24 
We assessed whether oxLDL regulates the expression of 
NR4A nuclear receptors (NR4A1 and NR4A3) in human 
CD4+ T cells. As shown in Figure 3E, oxLDL enhanced 
NR4A1 and NR4A3 mRNA expression in T-cell receptor–
activated human primary CD4+ T cells. An early induc-
tion of NR4A3 was also evoked by oxLDL in JKCD69 
cells but not in JKwt cells (Figure 3F), which was blocked 
by preincubation with anti-CD69 antibodies (Figure 3G) 
or shRNA, confirming the CD69-dependent effect of 
oxLDL (Figure 3H).
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Figure 1. CD69 deficiency in lymphoid cells aggravates atherosclerosis.  
A, Schematic illustrating the generation of lymphoid chimeras (LCs). Ldlr−/− (CD45.1+) mice were lethally irradiated and reconstituted with mixed bone marrow (BM) 
from Rag2−/−γc−/− plus BM from C57BL/6-Cd69+/+ (LC Cd69+/+) or C57BL/6-Cd69−/− (LC Cd69−/−) (double-reporter [dRep]; interleukin [IL]-17–green fluorescent protein 
[GFP]+/Foxp3–monomeric red fluorescent protein [RFP]+) mice at a 3:1 ratio, respectively. Reconstitution of the lymphoid and myeloid compartments of CD45.2+ 
cells was assessed by fluorescence-activated cell sorting. Peripheral blood mononuclear cells (PBMCs) after 8 weeks of reconstitution were >90% CD45.2+. 
Histograms show CD69 expression on CD4 and CD8 T cells, B cells (B), macrophages (Mac), monocytes (Mono), dendritic cells (DCs), and natural killer cells (NKs). 
PBMCs were stimulated overnight with anti–CD3/CD28 for lymphoid cells and lipopolysaccharide for myeloid cells of the indicated groups. B, Flow cytometry 
analysis of IL-17–GFP+ and Foxp3-RFP+ CD4 T cells in peripheral blood of LC CD69+/+ and LC CD69−/− mice after 14 weeks of a high fat diet (HFD). C, Percentage 
of Th17 (IL-17–GFP+), regulatory T (Treg; Foxp3-RFP+) CD4+ T cells, and Th17/Treg ratio in peripheral blood leukocytes of LC Cd69+/+ and LC Cd69−/− mice at the 
indicated time points after HFD initiation. n=15 mice per group (pooled from 3 independent experiments; error bars show SEM). P values were calculated by 2-way 
repeated-measures ANOVA (Sidak post hoc test). *P<0.05. **P<0.01. **** P<0.0001. D, Percentage and absolute numbers of IL-17–GFP+, Foxp3-RFP+ CD4 T cells 
in para-aortic lymph nodes (LN). n=12 mice per group. E. Oil Red O staining and quantification of plaque and necrotic core surface in aortic valves from LC Cd69+/+ 
and LC Cd69−/− mice after 16 weeks of HFD. n= 8 mice/group. F, As in E, Masson trichrome staining and fibrosis quantification. n=7 mice per group Original mag-
nification ×4. In D through F, error bars show SEM. *P<0.05, **P<0.01 as determined by unpaired t test or Mann-Whitney U test.
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In the in vivo model of atherosclerosis, the reporter 
GFP+ Th17 cells and oxLDL localized closely at the ather-
oma plaque. Moreover, CD3+ T cells and oxLDL colocal-
ized at atheroma plaque (Figure VIA and VIB in the on-
line-only Data Supplement). NR4A1 and NR4A3 mRNA 
expression was decreased in para-aortic LNs from BM 
Cd69−/− mice after 13 weeks of HFD (Figure 3I). More-
over, PBL expression of CD69 and NR4A1 transcripts 
gradually declined in ldlr−/− mice during HFD adminis-
tration (Figure 3J), indicating that these receptors are 
dynamically regulated in PBLs under these conditions.
CD69 Expression Is an Early Predictor of 
Subclinical Atherosclerosis
The PESA study is a prospective study that uses ad-
vanced imaging techniques to assess the presence of 
atheroma plaque in the main arteries of healthy individ-
uals. Having observed a significant downregulation of 
CD69 as plaque formation progressed in mice, we com-
pared CD69 and NR4A1 mRNA expression in PBLs from 
PESA participants with focal (1 affected site, n=55) or 
generalized (4–6 affected sites, n=128) subclinical ath-
erosclerosis with that of PESA participants without any 
evidence of subclinical atherosclerosis (n=122; Table 
I in the online-only Data Supplement). The extent of 
subclinical atherosclerosis was assessed with advanced 
imaging techniques.25 There is a gradient in CD69 ex-
pression across atherosclerosis extension stages; that is, 
CD69 expression decreases as disease progresses (trend 
test, P=0.006; Figure 4A). The same is true for NR4A1 
(trend test, P=0.003; Figure 4A). These differences were 
particularly significant for the generalized subclinical 
disease group (Figure 4B and 4C). Thus, we focused on 
Figure 2. CD69 binding to oxidized low-density lipoprotein (oxLDL).  
A, The LOX-1 and CD69 dimeric structures and their ligand-binding surfaces. Ribbon representations of the LOX-1 (Protein Data Bank code 1YXK) and CD69 (Pro-
tein Data Bank code 1E8i) C-type lectin-like domain (CTLD) structures (left; side views, prepared with PyMOL). Top views of the dimers with their surface charge 
distributions are shown on the right (prepared with GRASP). Arginine residues that form a basic “spine” across the dimer surface are labeled. B, Histograms show 
the binding of DiI-labeled oxLDL (solid line) to Jurkat T cells stably expressing CD69 (JKCD69) or rat basophilic leukemia cells (RBLCD69). Dotted line indicates 
the displacement of DiI-OxLDL by unlabeled lipoprotein. C, OxLDL binding to untransfected Jurkat T (JKwt) and JKCD69 cells (mean±SD from 10 independent 
experiments). *P<0.05 by Mann Whitney U test in both cell lines. D, Dose-response curves of oxLDL and native low-density lipoprotein (LDL) binding to JKwt and 
JKCD69 cells. E, CD69 internalization induced by oxLDL. JKCD69 cells were incubated with unlabeled oxLDL, and membrane-surface CD69 expression was ana-
lyzed by flow cytometry at the indicated times. Graph is representative of 1 of 3 experiments. F, Anti-CD69 antibodies inhibit the binding of oxLDL to JKCD69 cells 
(mean±SD from 4 experiments; *P<0.05). IgG1 indicates immunoglobulin G1; and MFI, mean fluorescence intensity.
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Figure 3. Oxidized low-density lipoprotein (OxLDL) binding to CD69 regulates the expression of NR4A receptors and cytokines in T cells.  
A, OxLDL effect on phorbol 12-myristate 13-acetate/ionomycin-induced expression of interferon-γ(IFN-γ) and interleukin (IL)-8 in untransfected Jurkat T (JKwt) and 
Jurkat T cells stably expressing CD69 (JKCD69) cells. Data correspond to fold induction of mRNA levels (IFN-γ, n=6; IL-8, n=4) analyzed with the Wilcoxon signed-rank 
test. *P<0.05. B through D, Binding of oxLDL to CD69 blocks Th1 and Th17 differentiation and promotes regulatory T (Treg) cells. Human CD4+ T-cell differentiation 
was carried out in the absence (control) or presence of oxLDL (50 µg/mL) or oxLDL+anti-CD69. After corresponding days of culture, the percent of IFN-γ+ T cells (B), 
percent of IL-17+ T cells (C), and percent of CD25+Foxp3+ T cells (D) were determined by flow cytometry. Data correspond to 4 independent experiments, and bars rep-
resent mean±SEM of percent of positive cells. Data were analyzed with the Friedman test and Dunn posttest. *P<0.05 vs control. E, OxLDL induces NR4A1 and NR4A3 
expression in activated human CD4+ T cells. Wilcoxon signed-rank test, *P<0.05 (n=4). F, Expression of NR4A3 in JKCD69 and JKwt cells treated (Continued )
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the control group (no disease) versus generalized dis-
ease group and examined whether CD69 can be used 
as independent marker for subclinical atherosclerosis. 
After a univariable logistic regression analysis (Table II 
in the online-only Data Supplement) of relevant vari-
ables (known cardiovascular risk factors: age, smoking, 
BMI, hypercholesterolemia, hypertension, diabetes mel-
litus, family history of cardiovascular disease; peripheral 
count of different subsets of leucocytes; expression of 
NR4A1 and the levels of oxLDL and C-reactive protein), 
a multivariable logistic regression analysis determined 
that CD69 expression remained an independent predic-
tor of atherosclerosis at an early stage (odds ratio, 0.62; 
P=0.0056; Table). Furthermore, CD69 levels correlated 
significantly with NR4A1 levels (Figure 4D and Table III 
in the online-only Data Supplement), supporting the 
notion of a common regulation pathway.
DISCUSSION
Our findings indicate that the absence of CD69 in the 
LC results in larger atheroma plaque formation in ldlr−/− 
deficient mice subjected to an HFD. We identify the 
functional interaction between CD69 and oxLDL as the 
mechanism responsible for the observed phenotype. 
Our clinical data support this concept because CD69 
expression in peripheral leucocytes of subjects with sub-
clinical atherosclerosis is downregulated compared with 
individuals without atherosclerosis. This finding was in 
agreement with the experimental evidence showing a 
downregulation of CD69 expression on T lymphocytes 
in mice on exposure to HFD. Despite a suggested role 
for oxLDL in adaptive immune responses, a putative re-
ceptor on T lymphocytes has remained elusive.32 Our 
study demonstrates that binding of oxLDL to CD69 in 
human T cells has a protective effect against the in-
flammatory response through the expression of NR4A 
nuclear receptors, downregulating proinflammatory cy-
tokines and promoting Treg differentiation.
Although the classic view is that oxLDL induces the 
recruitment of inflammatory cells to the subendo-
thelial space, cells and tissues also respond to oxLDL 
through the inhibition of proinflammatory signaling 
pathways.33,34 The NR4A subfamily of human nuclear 
receptors (NR4A1 [Nur77], NR4A2 [Nurr1] and NR4A3 
[NOR-1]) can be induced in endothelial and smooth 
muscle cells by a range of stimuli (including oxLDL), 
regulating the expression of different molecules in-
volved in the immune response.35 NR4A overexpres-
sion decreases the levels of IL-1β, IL-8, and monocyte 
chemoattractant protein-1 inflammatory cytokines. 
Furthermore, NR4A1 and NR4A3 have been impli-
cated in Treg differentiation.23,24 Our data show that 
binding of oxLDL to CD69 in human T cells induces the 
expression of NR4A receptors. Moreover, the absence 
of CD69 during atherosclerosis development results in 
a lower expression of NR4A1 and NR4A3 in both PBLs 
and para-aortic LNs. The observation of the regulatory 
effect of CD69/oxLDL interaction in human Treg dif-
ferentiation, together with the loss of Treg responses 
Figure 3 Continued. with oxLDL. Fold induction vs baseline (t=0). Data are mean±SD (n= 6) and were analyzed with 2-way ANOVA. ** P<0.0001, * P<0.01 vs 
JKwt at each time. G, Anti-CD69 inhibits oxLDL-induced NR4A3 expression in JKCD69 cells. Data are mean±SD (n= 6). Differences among groups were tested 
with the Kruskal-Wallis test. **P<0.001, *P<0.01 vs control. #P<0.02 vs oxLDL. H, shRNA silencing of CD69 expression blocks oxLDL-induced NR4A3 expression in 
JKCD69 cells. Data are mean±SD (n= 6). Data were analyzed with 2-way ANOVA. ** P<0.0001 vs shRNA CD69. I, mRNA levels of the indicated nuclear receptors 
in para-aortic lymph nodes from total bone marrow (BM) chimeras at 13 weeks after a high fat diet (HFD). n=5 mice per group. Error bars show SEM. *P<0.05, 
***P<0.001 as determined by unpaired t test. J, CD69 and NR4A1 mRNA relative expression in blood lymphocytes from ldlr−/− mice at different weeks after an 
HFD. Error bars show SEM. */&P<0.05, **/&&P<0.01, ***/&&&P<0.001 as determined by 1-way repeated-measures ANOVA. The Dunnett multiple-comparison test 
was performed between values at 5 to 11 weeks after an HFD vs 3 weeks after an HFD for CD69 (*) and NR4A1 (&) individually. AU indicates arbitrary units.
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observed in lymphocyte CD69-deficient mice during 
atherosclerosis development, suggests that the modu-
lation of NR4A nuclear receptors could participate in 
CD69 signaling/Treg differentiation. The more exten-
sive atherosclerosis developed in the absence of CD69 
could be associated, at least in part, with defects in 
Treg cell differentiation. Treg cells exert an atheropro-
tective function through the suppression of T-cell pro-
liferation and secretion of anti-inflammatory cytokines 
and are protective during the initial phases of athero-
sclerosis not only by reducing atherosclerotic plaque 
formation but also by improving stabilization of the 
atherosclerotic lesions.36–38
Besides promoting Treg cell function, CD69 controls 
Th17 differentiation through the association of its cy-
toplasmic tail with the Jak3/Stat5 signaling pathway, 
regulating RAR-related orphan receptor-γ transcription 
and differentiation toward the Th17 lineage.15 Recent 
evidence for the role of IL-17 in atherosclerosis has shed 
little light on the subject in both proatherogenic and 
antiatherogenic roles.39,40 Under HFD, ldlr−/− mice defi-
cient for CD69 in the LC developed exacerbated Th17 
responses and more severe atherosclerotic lesions, sup-
porting the role of IL-17 as a proatherogenic molecule. 
Despite previous reports supporting that IL-17 can ei-
ther stabilize the plaque through collagen production 
or enhance the recruitment of proatherogenic cells 
through CXCL1 upregulation,11,40 the former seems not 
to be the case in our model. Increased amounts of IL-17 
seem to stabilize plaque formation when levels of IL-
10 are also higher, namely in the presence of a proper 
Figure 4. Individuals with subclinical atherosclerosis express low levels of CD69 and NR4A1.  
A, mRNA expression of CD69 and NR4A1 is presented as mean±SEM in linear scale. Significance of the trend across groups was calculated with the Cuzick 
extension of the Wilcoxon rank-sum test to assess the significance of the trend across the 3 ordinal groups allowing for ties. B, mRNA levels of CD69 in peripheral 
blood leukocytes from healthy subjects (no disease [ND], n=122) and individuals with subclinical atherosclerosis (focal disease [FD], n=55; generalized disease 
[GD], n=128). C, mRNA levels of NR4A1 as in B. Data are expressed in log2 scale and were analyzed with 1-way ANOVA followed by Tukey posttests. * P<0.05. 
**P<0.005. D, Correlation between the expression of CD69 and NR4A1. The Pearson correlation test was used.
Table. Multivariable Logistic Regression Comparing Individuals 
With Generalized Subclinical Atherosclerosis and Individuals With No 
Disease
 Odds Ratio (95% CI) P Value
log2(CD69) 0.62 (0.40–0.94) 0.0056
log2(NR4A1) 1.12 (0.80–1.58) 0.0441
Age 1.21 (1.11–1.33) 0.0000
Familial hypercholesterolemia 2.06 (0.90–4.87) 0.0630
Hypercholesterolemia 1.13 (0.58–2.22) 0.1168
Smoking 2.16 (1.00–4.87) 0.0027
Monocytes 0.06 (0.00–1.61) 0.4733
Lymphocytes 1.57 (0.66 –3.82) 0.0025
Leukocytes 1.61 (1.11–2.41) 0.0079
Diabetes mellitus* Not applicable 0.0246
Oxidized low-density lipoprotein 1.02 (1.00–1.04) 0.0457
All covariates with a value of P<0.1 in the univariable analysis (Table II in the 
online-only Data Supplement) were considered. 
*P values were calculated with the likelihood ratio test to accommodate 
groups with 0 counts (diabetes mellitus), for which odds ratio estimates could 
not be calculated. Odds ratio and CIs were estimated with a generalized linear 
model.
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regulatory response.39 In our model, however, we have 
a concomitant increase of IL-17 and defective Treg de-
velopment and function.
Previous results indicated that the regulatory action 
of CD69 during atherosclerosis was lost in ApoE−/− 
mice because, compared with the double-knockout 
group (Cd69−/−ApoE−/−), no significant difference was 
observed in plaque formation.20 LDLr−/− and ApoE−/− 
mice have been extensively used to study the mecha-
nisms of atherosclerosis development but feature im-
portant differences, for example, in plasma proteins. 
The major accumulating lipoprotein in the plasma of 
LDLr−/− mice fed a high-cholesterol diet is LDL. Con-
versely, ApoE−/− mice accumulate cholesterol mostly in 
the very-low-density lipoprotein and chylomicron frac-
tions.41,42 This is a very important issue to be consid-
ered that could account for the differences observed 
between CD69−/−/apoE−/− and CD69−/−/Ldlr−/− models. 
Our data show that oxLDL binding to CD69 exerts an 
immune-regulatory function during atherosclerosis 
development. In the ApoE knockout model, the levels 
of LDL may not have reached the threshold that is re-
quired for signaling through CD69. An additional dif-
ference that should be taken into consideration is that 
Ldlr−/− lesions have higher T-cell density than the ApoE 
model,43 meaning that Ldlr−/− mice have more T cells 
that could express CD69 to exert their function. Finally, 
ApoE−/− mice on an HFD develop plaques more rapidly 
and exhibit larger aortic lesions with larger necrotic 
cores than Ldldr−/− mice41,42; therefore, this high-inten-
sity model could be masking the differences between 
the CD69-expressing and CD69-deficient animals. We 
found a significant decrease in the blood lipid profile 
of free fatty acids, triglycerides, high-density lipopro-
tein, LDL, and cholesterol in the Cd69−/− lymphoid chi-
meras. This “dissociation” of the immune profile of 
the organism from the metabolic parameters is quite 
intriguing; it seems to occur via mechanisms related 
mainly to the adaptive immune responses (in this case, 
lack of CD69 and Th17 propensity). Our data pave the 
way for further research on mechanisms that could 
contribute to atherogenesis.
Our results describe for the first time an oxLDL re-
ceptor on lymphocytes with an important function 
in the regulation of the adaptive immune response 
and atheroma plaque formation during an HFD. The 
chimeric ldlr−/− mouse models used shed light on the 
role of CD69/oxLDL functional interaction in lympho-
cytes and on the maintenance of immune homeo-
stasis to protect medium and large arteries from se-
vere atheroma plaque formation over time. Further 
studies of the new regulatory oxLDL/CD69 pair in 
human lymphoid cells during atherosclerotic disease 
progression will provide novel insight into targeting 
these pathways for the prognosis/treatment of car-
diovascular diseases.
Recent data emphasized the link between the in-
flammatory response and atherosclerotic risk in the 
clinical arena.2 However, the complex interplay be-
tween lipid metabolism and immune responses re-
mains to be fully disclosed. Collectively, our in vivo 
data strongly indicate an important role for CD69 ex-
pression on lymphocytes during atherosclerosis devel-
opment. To validate this new paradigm in humans, we 
assessed the expression of CD69 and NR4A in PBLs 
from a cohort of subjects with thoroughly character-
ized subclinical atherosclerosis. It is important to point 
out that all PESA participants included in the study 
were asymptomatic and free of events. The profile of 
CD69 expression detected in human samples was very 
similar to that observed in the in vivo model. If we con-
sider focal disease and generalized disease as differ-
ent stages with the same pathology, our data indicate 
that expression of CD69 gradually declines as disease 
progresses. Hence, we focused on the generalized dis-
ease group, which is still preclinical, to assess the as-
sociation of the expression of CD69 with subclinical 
atherosclerosis, accounting for the effect of traditional 
risk factors, peripheral counts of different subsets of 
leucocytes, expression of NR4A1, and levels of oxLDL. 
The proof of clinical study more closely resembling the 
animal experiments was to compare subjects free of 
disease or no disease versus those with established 
but yet subclinical atherosclerosis or generalized sub-
clinical disease. CD69 remained significantly associ-
ated with the extent of the disease after adjustment 
for risk factors. This finding underscores the putative 
role of CD69 as a potential marker for the detection of 
atherosclerosis at a preclinical stage.
The fact that atherosclerosis presence is well identi-
fied in a context different from acute conditions (eg, 
myocardial infarction) supports the causative role of 
CD69 expression on atherosclerosis development rather 
than a consequence of an acute event.
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